Granules

This Hyderabad company, maker of pharmaceutical compounds in granular form posted a weak performance for Q4FY15 with a 8% (YoY) drop in consolidated net profit at Rs.22 crore. Net sales rose 12% at Rs.355 crore but a 15% surge in costs pulled down the bottomline. The rise in costs was on account of a 19% rise in raw material cost, employee cost rising 13%,depreciation going up 40%, manufacturing costs rising 29% and R&D expenses more than doubling to Rs.7 crore. It ended FY15 with a net profit of Rs.91 crore, up 21%.

Finished dosage continued to remain the largest contributor to revenue at 38%, PFI contribution was at 28% and API at 34%. Sales to the regulated markets for FY15 rose 69% v/s 65% increase in FY14.  Auctus Pharma turned around during Q4, contributing positively to the consolidated numbers. It recently started its API facility in Vizag with its partner, Ajinimoto OmniChem. The US FDA completed successful inspection of its facilities at Bonthapally and Gagillapur.